ClinicalTrials.gg
RecruitingNCT07353671Updated Mar 25, 2026

Topical Periplaneta Americana-Derived Meilian Fuxin Liquid for Radiation Dermatitis

A Phase 2/3 interventional study of Topical application of Periplaneta americana-derived Meilian Fuxin Solution and Topical application of placebo in Radiation-induced Dermatitis, sponsored by West China Hospital. Recruiting at 2 sites in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-03-25.

Sponsored by West China Hospital · Phase 2/3, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 17 studies in Radiodermatitis with a site in China — 12 open to participants now, 12 under way, 2 of them phase 3. Radiodermatitis · China.

Planned enrollment
9th of 15
60 · median 68
Started
2026
with 3 others
Phase 2/3
Only one
of the 17
Primary completion
2026-12
later than 8 of 11 live
Registered
14th of 17
by date
Lead sponsor
6 of 17
West China Hospital

Among the 17 studies in Radiodermatitis with a site in China, this one is the 9th largest by planned enrollment of the 15 interventional ones that give a count, is one of 4 that started in 2026, is the only one in phase 2/3, reaches primary completion later than 8 of the 11 other live ones, and was the 14th registered.

Radiodermatitis

128 studies on the registry are indexed under Radiodermatitis; 27 are open to participants now.

Browse Radiodermatitis studies →

Open to participants now

12 of the 17 studies in Radiodermatitis with a site in China are open now. Recruiting first, the newest first:

6 more — sign in →

All 12 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 20 Radiodermatitis studies recruiting now, 6 (30%) set no upper age limit and 6 (30%) stop at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Radiodermatitis with a site in China, or all of them as a file.
02

Study summary

To evaluate the efficacy and safety of topical Periplaneta americana-derived Meilian Fuxin Solution for the prevention of radiation dermatitis in patients undergoing radiotherapy.

Read the detailed description

The clinical trial aims to evaluate the efficacy and safety of topical Periplaneta americana-derived Meilian Fuxin Solution in preventing and reducing radiation dermatitis in patients undergoing radiotherapy. Participants will be assigned to receive either topical Meilian Fuxin Solution or a placebo formulation, applied twice daily to the irradiated skin area from the start of radiotherapy through completion of treatment. The placebo will be administered using an identical application regimen. Radiation dermatitis will be assessed at baseline and at regular intervals during and after radiotherapy using the Radiation Therapy Oncology Group (RTOG) criteria, and safety will be evaluated by monitoring local and systemic adverse events throughout the study period.

03

Conditions studied

  • Radiation-induced Dermatitis

Keywords

  • Head & neck cancer
  • Radiation-induced Dermatitis
  • Meilian Fuxin Solution
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age and Gender: Patients aged 18 to 80 years (inclusive of boundary values), regardless of gender.
  2. Diagnosis and Treatment: Patients with head and neck cancer (including nasopharyngeal carcinoma) who have been confirmed by histopathology and require radical radiotherapy or postoperative radiotherapy.
  3. Performance Status: Patients with an Performance Status score of 0 to 2.
  4. Consent: Patients who voluntarily agree to participate in this study and sign the form.

Exclusion criteria

Exclusion Criteria:

  1. Prior Radiotherapy: Patients with a history of prior radiotherapy to the target area.
  2. Baseline Skin Condition: Baseline skin condition in the treatment area that may interfere with efficacy assessment (e.g., presence of open wounds, infection, rash, psoriasis, etc.).
  3. Systemic Diseases: Presence of connective tissue diseases or other systemic dermatoses.
  4. Known Allergies: Known allergy to any component of the product (Meilian Fuxin Solution).
  5. Prior Clinical Research: Participation in other interventional clinical studies within the past 3 months and use of any investigational drugs or devices.
  6. Investigator Discretion: Subjects judged by the investigator to be unsuitable for participation in this clinical study.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Meilian Fuxin Solution

    Topical application of Periplaneta americana-derived Meilian Fuxin Solution

    Drug: Topical application of Periplaneta americana-derived Meilian Fuxin Solution · Radiation: Radiotherapy

  • Placebo comparator
    Control group

    Topical application of placebo

    Other: Topical application of placebo · Radiation: Radiotherapy

Interventions

  • DrugTopical application of Periplaneta americana-derived Meilian Fuxin Solution

    A topical formulation derived from Periplaneta americana (Meilian Fuxin Solution).

    Also known as: MLFX, Periplaneta Americana Extract, Meilian Fuxin Ye

  • OtherTopical application of placebo

    The placebo topical formulation will be composed of inactive ingredients and will be matched in appearance, texture, and administration regimen to the active Periplaneta americana-derived Meilian Fuxin Solution, and participants will also receive standard skin care for radiation dermatitis according to institutional clinical practice guidelines.

  • RadiationRadiotherapy

    One of the inclusion criteria for the study was that patients with squamous carcinoma of the head and neck (including nasopharyngeal carcinoma) needed to receive either radiotherapy alone or simultaneous radiotherapy and chemotherapy.

06

What researchers measure

Primary outcomes

  1. Incidence of Grade 2 or Higher Acute Radiation Dermatitis (RTOG Criteria)

    Acute radiation dermatitis is assessed by trained radiation oncologists according to the Radiation Therapy Oncology Group (RTOG) acute radiation morbidity scoring criteria. The RTOG grading system categorizes acute radiation dermatitis into grades 0 to 4, with higher grades indicating more severe skin reactions. Grade 0 indicates no visible skin changes; Grade 1 indicates faint erythema or dry desquamation; Grade 2 indicates moderate to brisk erythema or patchy moist desquamation, mainly confined to skin folds; Grade 3 indicates confluent moist desquamation outside of skin folds or bleeding induced by minor trauma; and Grade 4 indicates skin necrosis or ulceration of full-thickness dermis, or spontaneous bleeding. The incidence of Grade 2 or higher acute radiation dermatitis is defined as the proportion of participants who develop Grade 2, Grade 3, or Grade 4 dermatitis at any time during radiotherapy or within the post-radiotherapy follow-up period.

    Time frame: The evaluation period is approximately 14 weeks to 14.5 weeks.

Secondary outcomes

  1. Incidence of Grade 3 or Grade 4 Radiation Dermatitis

    Radiation dermatitis is assessed by trained physicians according to the Radiation Therapy Oncology Group (RTOG) acute radiation morbidity scoring criteria.

    Time frame: The evaluation period is approximately 14 weeks and 14.5 weeks.

  2. Time to Occurrence of Grade 3 or Grade 4 Radiation Dermatitis

    The time from the start of radiotherapy to the first documented occurrence of Grade 3 or Grade 4 radiation dermatitis, as assessed according to the Radiation Therapy Oncology Group (RTOG) acute radiation morbidity scoring criteria.

    Time frame: The evaluation period is approximately 14 weeks to 14.5 weeks.

  3. The duration of any-grade Radiation Dermatitis

    The first determination of radiation dermatitis to the first instance of non-radiation dermatitis, without a subsequent instance of radiation dermatitis.

    Time frame: The evaluation period is approximately 14 weeks and 14.5 weeks.

  4. Change in Radiation Dermatitis Severity Score using the RISRAS Scale

    The change in radiation dermatitis severity, as measured by the Radiation-Induced Skin Reaction Assessment Scale (RISRAS), which ranges from 0 to 24, with higher scores indicating more severe skin reactions. Scores will be assessed at baseline (before the first day of radiotherapy), weekly during radiotherapy, and at follow-up visits up to 8 weeks after completion of radiotherapy.

    Time frame: The evaluation period is approximately 14 weeks and 14.5 weeks.

  5. Change in Patient Quality of Life using the Skindex-16

    The change in patient-reported quality of life related to skin symptoms, as measured by the Skindex-16 Dermatology Life Quality Instrument, which ranges from 0 to 100, with higher scores indicating worse quality of life. Scores will be assessed at baseline (before the first day of radiotherapy), weekly during radiotherapy, and at follow-up visits up to 8 weeks after completion of radiotherapy.

    Time frame: The evaluation period is approximately 14 weeks and 14.5 weeks.

  6. Radiotherapy Interruption due to Radiation Dermatitis

    The occurrence of any temporary interruption, delay, or discontinuation of radiotherapy attributable to radiation dermatitis, as documented in the medical record. The reason for interruption will be confirmed by the treating radiation oncologist.

    Time frame: The time period is the period from the start of radiotherapy to the completion of radiotherapy.The evaluation period is approximately 6 weeks and 6.5 weeks.

  7. Adverse events

    Common Terminology Criteria for Adverse Events (CTCAE) 5.0 version

    Time frame: The evaluation period is approximately 14 weeks and 14.5 weeks.

Other outcomes

  1. Overall Health Status and Core Dimensions of Quality of Life

    European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) This instrument is a 30-item patient-reported outcome (PRO) measure designed to evaluate core aspects of health-related quality of life in cancer patients, including 5 functional scales (physical, role, cognitive, emotional, social), 3 symptom scales (fatigue, pain, nausea and vomiting), one global health status/quality of life scale, and 6 single-item symptom measures. Scores are linearly transformed to a range of 0-100. For the functional scales and the global health status scale, higher scores indicate better functional levels or quality of life; for the symptom scales/items, higher scores indicate greater symptom burden.

    Time frame: The total evaluation period is approximately 14 to 14.5 weeks.

  2. Head and Neck Cancer-Specific Symptoms

    The EORTC QLQ-H\&N35 is a patient-reported outcome (PRO) instrument specifically designed to assess disease-related symptoms and treatment-related side effects in patients with head and neck cancer. It comprises 35 items, organized into seven multi-item subscales (pain, swallowing, senses, speech, social eating, social contact, and sexuality) and eleven single-item measures (such as dental problems, problems opening mouth, sticky saliva, coughing, etc.). All subscale and single-item scores are linearly transformed to a 0-100 scale using a standardized scoring algorithm. Interpretation of Scores: For all subscales and single items, higher scores represent more severe symptoms or greater symptom burden.

    Time frame: The total evaluation period is approximately 14 to 14.5 weeks.

  3. The number of patients who missed five or more consecutive radiation fractions

    The number of patients who missed five or more consecutive radiations and the reasons for this are recorded during radiotherapy.

    Time frame: The evaluation period is approximately 6 weeks and 6.5 weeks.

07

Study locations

2 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2026 (actual). Primary completion is estimated for Dec 2026, 9 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 14, 2025
First posted
Jan 20, 2026
StartActual
Mar 1, 2026
Primary completionEst.
Dec 31, 2026
CompletionEst.
Jun 30, 2027
Last update
Mar 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 25, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07353671
Responsible party
Xingchen Peng (PhD, Professor, West China Hospital) — Principal investigator
First posted
Jan 20, 2026
Start date
Mar 1, 2026
Primary completion
Dec 31, 2026 (estimated)
Completion
Jun 30, 2027 (estimated)
Last update
Mar 25, 2026

Study contacts

Xingchen Peng
Contact
pxx2014@163.com
+86 18980606753
Ruiwan Yuan
Contact
yuanruiwan@outlook.com
Xingchen Peng
principal investigator · West China Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion